Market atlas / Senolytics / Dasatinib

Dasatinib (senolytic use)

repurposedsmall-moleculesenolyticbcr-abl-inhibitionsrc-family-kinase-inhibition● senescent-cell-burden

Stage by geography

Same development stage across markets, but South Korea reached it about 17 years before United Kingdom.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNJPCHSGILKRIN+1 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	approved	not dated	form Oral
UK	approved	2024-06-27	indication Dasatinib is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in…
CN	approved	not dated	form Tablet, chemical drug
IN	RCT	2008-10-01	not published
JP	approved	2009-01-21	indication Drugs containing a new active ingredient indicated for the treatment of 1) imatinib-resistant chronic myelogenous leukemia and 2) recurrent or refractory…
CH	approved	2007-02-02	indication Philadelphia-chromosome-positive chronic myeloid leukemia Philadelphia-chromosome-positive acute lymphoblastic leukemia
SG	approved	2007-09-14	form Tablet, film coated, oral, prescription only
IL	approved	2022-06-26	indication Treatment of adult patients with : * Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. *…
KR	approved	2007-01-25	class Antineoplastic agents [MFDS 04210]

China registers · NMPA

What each NMPA register actually approved. Reference approval NMPA H20133271. Domestic generics vs imported originator.

12domestic approvals

Forms listed: 2
Product: Dasatinib Tablets
Form: tablet
Strength: 20mg
Holder: Chia Tai Tianqing Pharmaceutical Group
Origin: China
Approved: 2023-07-13
Approval no: NMPA H20133271

6imported approvals

approval count only; per-product detail not captured

Biomarker trends

no biomarker readings yet

Studies

The studies on Dasatinib, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI	CH, IL, IN, JP, KR, SG
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected…	CH, IL, IN, JP, KR, SG
Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment -…	CH, IL, KR, SG
CMR as determined by two consecutive (-) RT-PCR tests for the presence of BCR-ABL transcripts in peripheral blood samples 1 year…	CH
Rate of complete molecular response (CMR) after treatment with dasatinib	JP
Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24	JP

Connections

Trajectory

2007

MarketKR: approved-other (MFDS-approved (South Korea))

MFDS:dasatinib (2007-01-25) · machine-extracted

2007

MarketCH: approved-other (Swissmedic-authorised (Switzerland))

Swissmedic:dasatinib (2007-02-02) · machine-extracted

2007

MarketSG: approved-other (HSA-registered (Singapore))

HSA:dasatinib (2007-09-14) · machine-extracted

2008

MarketIN: rct (clinical trials (highest phase 3))

NCT00744497 · machine-extracted

2009

MarketJP: approved-other (PMDA-approved (Japan))

PMDA:dasatinib (2009-01-21) · machine-extracted

2016

Relatedshares a mechanism with Fisetin

NCT02848131 · machine-extracted

2016

Relatedcontrasts with Rapamycin

NCT02848131 · machine-extracted

2016

ProfileDasatinib (senolytic use)

NCT02848131 · machine-extracted

2022

MarketIL: approved-other (Israel MoH-registered)

IsraelMoH:dasatinib (2022-06-26) · machine-extracted

2024

MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)

EMC:dasatinib (product 101682) · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 2))

NCT00568750 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 2))

NCT00103844 · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 2))

NCT00337454 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 2))

NCT01593254 · machine-extracted

2026

MarketSG: rct (clinical trials (highest phase 2))

NCT00777036 · machine-extracted

2026

MarketCN: approved-other (NMPA-approved (domestic + imported))

NMPA:NMPA H20133271 · machine-extracted

2026

MarketUS: approved-other (approved, marketed)

NDA021986 · machine-extracted

Get into the weeds: raw observations + provenance

mfds__dev_dasatinib__KR  2026-07-13  kind=geography_stage  verify=M
   MFDS-approved in South Korea: Dasatinib (SPRYCEL TAB. 70MG), first approval 2007-01-25. [MFDS drug product-approval list]
   source MFDS:dasatinib (2007-01-25)  https://nedrug.mfds.go.kr/pbp/CCBGA01

swissmedic__dev_dasatinib__CH  2026-07-13  kind=geography_stage  verify=M
   Swissmedic-authorised in Switzerland: dasatinibum (Sprycel 20 mg, film-coated tablets), first authorisation 2007-02-02. [Swissmedic list of authorised medicinal products]
   source Swissmedic:dasatinib (2007-02-02)  https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/erweiterte_ham_ind.xlsx

hsa__dev_dasatinib__SG  2026-07-13  kind=geography_stage  verify=M
   HSA-registered in Singapore: DASATINIB (SPRYCEL TABLETS 50MG), first registration 2007-09-14. [HSA Listing of Registered Therapeutic Products]
   source HSA:dasatinib (2007-09-14)  https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view

dasa_in  2026-06-29  kind=geography_stage  verify=M
   Dasatinib: registered phase 3 trials in India [NCT00744497]
   source NCT00744497  https://clinicaltrials.gov/study/NCT00744497

pmda__dev_dasatinib__JP  2026-07-13  kind=geography_stage  verify=M
   PMDA-approved in Japan: Dasatinib hydrate (Sprycel Tablets 20 mg Sprycel Tablets 50 mg (Bristol-Myers K.K.)), first approval 2009-01-21. [PMDA List of Approved Drugs]
   source PMDA:dasatinib (2009-01-21)  https://www.pmda.go.jp/files/000281190.pdf

dasa_edge_fise  2026-06-29  kind=edge  verify=M
   both senolytics
   source NCT02848131  https://clinicaltrials.gov/study/NCT02848131

dasa_edge_rapa  2026-06-29  kind=edge  verify=M
   senolytic (clears senescent cells) vs mTOR inhibition, different anti-aging pathway
   source NCT02848131  https://clinicaltrials.gov/study/NCT02848131

dasa_facets  2026-06-29  kind=facets  verify=M
   Dasatinib facets
   source NCT02848131  https://clinicaltrials.gov/study/NCT02848131

israelmoh__dev_dasatinib__IL  2026-07-13  kind=geography_stage  verify=M
   Registered in Israel (Israeli Drug Registry): DASATINIB AS MONOHYDRATE 100 MG (DASATINIB TEVA 100 MG), current registration 2022-06-26. [Israel MoH Drug Registry]
   source IsraelMoH:dasatinib (2022-06-26)  https://israeldrugs.health.gov.il/

dasa_uk  2026-07-14  kind=geography_stage  verify=M
   UK marketing authorisation (MHRA), per the eMC SmPC: Dasatinib 100 mg film-coated tablets [active substance: Dasatinib anhydrous], first authorised 2024-06-27. [electronic Medicines Compendium, medicines.org.uk]
   source EMC:dasatinib (product 101682)  https://www.medicines.org.uk/emc/product/101682/smpc

ctsearch__CH__dev_dasatinib  2026-07-10  kind=geography_stage  verify=M
   dasatinib: 14 registered trial(s) in CH, highest phase 2 [NCT00568750]
   source NCT00568750  https://clinicaltrials.gov/study/NCT00568750

ctsearch__IL__dev_dasatinib  2026-07-10  kind=geography_stage  verify=M
   dasatinib: 11 registered trial(s) in IL, highest phase 2 [NCT00103844]
   source NCT00103844  https://clinicaltrials.gov/study/NCT00103844

ctsearch__JP__dev_dasatinib  2026-07-10  kind=geography_stage  verify=M
   dasatinib: 11 registered trial(s) in JP, highest phase 2 [NCT00337454]
   source NCT00337454  https://clinicaltrials.gov/study/NCT00337454

ctsearch__KR__dev_dasatinib  2026-07-10  kind=geography_stage  verify=M
   dasatinib: 21 registered trial(s) in KR, highest phase 2 [NCT01593254]
   source NCT01593254  https://clinicaltrials.gov/study/NCT01593254

ctsearch__SG__dev_dasatinib  2026-07-10  kind=geography_stage  verify=M
   dasatinib: 13 registered trial(s) in SG, highest phase 2 [NCT00777036]
   source NCT00777036  https://clinicaltrials.gov/study/NCT00777036

nmpa__dev_dasatinib__CN  2026-07-13  kind=geography_stage  verify=M
   NMPA-approved in China (dasatinib): 12 domestic approval(s) (e.g. Dasatinib Tablets, 20mg, Chia Tai Tianqing Pharmaceutical Group, China); 6 imported approval(s). Reference NMPA H20133271.
   source NMPA:NMPA H20133271  https://www.nmpa.gov.cn/datasearch/home-index.html

openfda__NDA021986__US  2026-07-13  kind=geography_stage  verify=M
   FDA-approved in the US (DASATINIB); approved, marketed [NDA021986]
   source NDA021986  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA021986